Generation and characterization of six recombinant botulinum neurotoxins as reference material to serve in an international proficiency test

Toxins

Volumn 7, Issue 12, 2015, Pages 5035-5054

  Weisemann, Jasmin ^a   Krez, Nadja ^a   Fiebig, Uwe ^b   Worbs, Sylvia ^b   Skiba, Martin ^b   Endermann, Tanja ^b   Dorner, Martin B ^b   Bergström, Tomas ^c   Muñoz, Amalia ^d   Zegers, Ingrid ^d   Müller, Christian ^f   Jenkinson, Stephen P ^f   Avondet, Marc Andre ^f   Delbrassinne, Laurence ^e   Denayer, Sarah ^e   Zeleny, Reinhard ^d   Schimmel, Heinz ^d   Åstot, Crister ^c   Dorner, Brigitte G ^b   Rummel, Andreas ^a  

^a Toxogen GmbH   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c SWEDISH DEFENCE RESEARCH AGENCY   (Sweden)

^d JOINT RESEARCH CENTRE   (Italy)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^f Spiez Laboratory   (Switzerland)

Author keywords

Botulinum neurotoxin; Characterization; Mass spectrometric identification; Recombinant expression; Reference material; Specific activity

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN C; BOTULINUM TOXIN D; BOTULINUM TOXIN E; BOTULINUM TOXIN F; UNCLASSIFIED DRUG; NEUROTOXIN; RECOMBINANT PROTEIN; SNARE PROTEIN;

ACUTE TOXICITY; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DNA FINGERPRINTING; ENDOPEP MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEMIDIAPHRAGM; ISOTOPE DILUTION ASSAY; LD50; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHRENIC NERVE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DETERMINATION; PROTEIN PURIFICATION; RECOMBINANT DNA TECHNOLOGY; TANDEM MASS SPECTROMETRY; ANIMAL; CHEMISTRY; DRUG EFFECTS; GOOD LABORATORY PRACTICE; PHYSIOLOGY; STANDARD; STANDARDS;

ANIMALS; BOTULINUM TOXINS; FEMALE; LABORATORY PROFICIENCY TESTING; LETHAL DOSE 50; MICE; NEUROTOXINS; PHRENIC NERVE; RECOMBINANT PROTEINS; REFERENCE STANDARDS; SNARE PROTEINS;

EID: 84948820451     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins7124861     Document Type: Article

References (61)

1. Rummel, A. The long journey of Botulinum Neurotoxins into the Synapse. Toxicon 2015, 107, 9-24. [CrossRef] [PubMed]
2. Bigalke, H.; Rummel, A. Medical aspects of toxin weapons. Toxicology 2005, 214, 210-220. [CrossRef] [PubMed]
3. Bigalke, H. Botulinum toxin: Application, safety, and limitations. Curr. Top. Microbiol. Immunol. 2013, 364, 307-317. [PubMed]
4. Hill, K.K.; Smith, T.J. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr. Top. Microbiol. Immunol. 2013, 364, 1-20. [PubMed]
5. Dorner, M.B.; Schulz, K.M.; Kull, S.; Dorner, B.G. Complexity of botulinum neurotoxins: Challenges for detection technology. Curr. Top. Microbiol. Immunol. 2013, 364, 219-255. [PubMed]
6. Gu, S.; Rumpel, S.; Zhou, J.; Strotmeier, J.; Bigalke, H.; Perry, K.; Shoemaker, C.B.; Rummel, A.; Jin, R. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 2012, 335, 977-981. [CrossRef] [PubMed]
7. Matsui, T.; Gu, S.; Lam, K.H.; Carter, L.G.; Rummel, A.; Mathews, I.I.; Jin, R., II. Structural basis of the pH-dependent assembly of a botulinum neurotoxin complex. J. Mol. Biol. 2014, 426, 3773-3782. [CrossRef] [PubMed]
8. Lam, K.H.; Jin, R. Architecture of the botulinum neurotoxin complex: A molecular machine for protection and delivery. Curr. Opin. Struct. Biol. 2015, 31, 89-95. [CrossRef] [PubMed]
9. Lee, K.; Gu, S.; Jin, L.; Le, T.T.; Cheng, L.W.; Strotmeier, J.; Kruel, A.M.; Yao, G.; Perry, K.; Rummel, A.; et al. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog. 2013, 9, e1003690. [CrossRef] [PubMed]
10. Lee, K.; Zhong, X.; Gu, S.; Kruel, A.M.; Dorner, M.B.; Perry, K.; Rummel, A.; Dong, M.; Jin, R. Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex. Science 2014, 344, 1405-1410. [CrossRef] [PubMed]
11. Lee, K.; Lam, K.H.; Kruel, A.M.; Mahrhold, S.; Perry, K.; Cheng, L.W.; Rummel, A.; Jin, R. Inhibiting oral intoxication of botulinum neurotoxin A complex by carbohydrate receptor mimics. Toxicon 2015, 107, 43-49. [CrossRef] [PubMed]
12. Montal, M. Botulinum neurotoxin: A marvel of protein design. Ann. Rev. Biochem. 2010, 79, 591-617. [CrossRef] [PubMed]
13. Brunger, A.T.; Rummel, A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon 2009, 54, 550-560. [CrossRef] [PubMed]
14. Lindström, M.; Korkeala, H. Laboratory diagnostics of botulism. Clin. Microbiol. Rev. 2006, 19, 298-314. [CrossRef] [PubMed]
15. Worbs, S.; Fiebig, U.; Zeleny, R.; Schimmel, H.; Rummel, A.; Luginbühl, W.; Dorner, B.G. Qualitative and Quantitative Detection of Botulinum Neurotoxins from Complex Matrices: Results of the First International Proficiency Test. Toxins 2015, 7. [CrossRef]
16. Hedeland, M.; Moura, H.; Baverud, V.;Woolfitt, A.R.; Bondesson, U.; Barr, J.R. Confirmation of botulism in birds and cattle by the mouse bioassay and Endopep-MS. J. Med. Microbiol. 2011, 60, 1299-1305. [CrossRef] [PubMed]
17. Lindström, M.; Myllykoski, J.; Sivela, S.; Korkeala, H. Clostridium botulinum in cattle and dairy products. Crit. Rev. Food sci. Nutr. 2010, 50, 281-304. [CrossRef] [PubMed]
18. Woudstra, C.; le Marechal, C.; Souillard, R.; Bayon-Auboyer, M.H.; Anniballi, F.; Auricchio, B.; De Medici, D.; Bano, L.; Koene, M.; Sansonetti, M.H.; et al. Molecular gene profiling of Clostridium botulinum group III and its detection in naturally contaminated samples originating from various European countries. Appl. Environ. Microbiol. 2015, 81, 2495-2505. [CrossRef] [PubMed]
19. Gil, L.A.; da Cunha, C.E.; Moreira, G.M.; Salvarani, F.M.; Assis, R.A.; Lobato, F.C.; Mendonca, M.; Dellagostin, O.A.; Conceicao, F.R. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D. PLoS ONE 2013, 8, e69692. [CrossRef] [PubMed]
20. Frevert, J. Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products. Drugs R D 2015, 15, 1-9. [CrossRef] [PubMed]
21. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680-685. [CrossRef] [PubMed]
22. Bergström, T.; Fredriksson, S.A.; Nilsson, C.; Astot, C. Deamidation in ricin studied by capillary zone electrophoresis- and liquid chromatography-mass spectrometry. J. Chromatogr. B 2015, 974, 109-117. [CrossRef] [PubMed]
23. Pauly, D.; Kirchner, S.; Stoermann, B.; Schreiber, T.; Kaulfuss, S.; Schade, R.; Zbinden, R.; Avondet, M.A.; Dorner, M.B.; Dorner, B.G. Simultaneous quantification of five bacterial and plant toxins from complex matrices using a multiplexed fluorescent magnetic suspension assay. Analyst 2009, 134, 2028-2039. [CrossRef] [PubMed]
24. Weingart, O.G.; Schreiber, T.; Mascher, C.; Pauly, D.; Dorner, M.B.; Berger, T.F.; Egger, C.; Gessler, F.; Loessner, M.J.; Avondet, M.A.; et al. The case of botulinum toxin in milk: Experimental data. Appl. Environ. Microbiol. 2010, 76, 3293-3300. [CrossRef] [PubMed]
25. Pauly, D.; Dorner, M.; Zhang, X.; Hlinak, A.; Dorner, B.; Schade, R. Monitoring of laying capacity, immunoglobulin Y concentration, and antibody titer development in chickens immunized with ricin and botulinum toxins over a two-year period. Poult. Sci. 2009, 88, 281-290. [CrossRef] [PubMed]
26. Simon, S.; Fiebig, U.; Liu, Y.; Tierney, R.; Dano, J.; Worbs, S.; Endermann, T.; Nevers, M.-C.; Volland, H.; Sesardic, D.; et al. Recommended Immunological Strategies to Screen for Botulinum Neurotoxin- Containing Samples. Toxins 2015, 7. [CrossRef]
27. Muñoz, A.; Kral, R.; Schimmel, H. Quantification of protein calibrants by amino acid analysis using isotope dilution mass spectrometry. Anal. Biochem. 2011, 408, 124-131. [CrossRef] [PubMed]
28. Rummel, A.; Bade, S.; Alves, J.; Bigalke, H.; Binz, T. Two carbohydrate binding sites in the HCC-domain of tetanus neurotoxin are required for toxicity. J. Mol. Biol. 2003, 326, 835-847. [CrossRef]
29. Bigalke, H.; Rummel, A. Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN). Toxins 2015, 7. [CrossRef]
30. Reed, L.J.; Muench, H. A simple method of estimating 50% endpoints. Am. J. Hyg. 1938, 27, 493-497.
31. Pearce, L.B.; Borodic, G.E.; First, E.R.; MacCallum, R.D. Measurement of botulinum toxin activity: Evaluation of the lethality assay. Toxicol. Appl. Pharmacol. 1994, 128, 69-77. [CrossRef] [PubMed]
32. Rummel, A.; Mahrhold, S.; Bigalke, H.; Binz, T. TheHCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 2004, 51, 631-643. [CrossRef] [PubMed]
33. Rummel, A.; Häfner, K.; Mahrhold, S.; Darashchonak, N.; Holt, M.; Jahn, R.; Beermann, S.; Karnath, T.; Bigalke, H.; Binz, T. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J. Neurochem. 2009, 110, 1942-1954. [CrossRef] [PubMed]
34. Strotmeier, J.; Lee, K.; Völker, A.K.; Mahrhold, S.; Zong, Y.; Zeiser, J.; Zhou, J.; Pich, A.; Bigalke, H.; Binz, T.; et al. Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem. J. 2010, 431, 207-216. [CrossRef] [PubMed]
35. Rummel, A.; Mahrhold, S.; Bigalke, H.; Binz, T. Exchange of the HCC domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin. FEBS J. 2011, 278, 4506-4515. [CrossRef] [PubMed]
36. Kalb, S.R.; Krilich, J.C.; Dykes, J.K.; Luquez, C.; Maslanka, S.E.; Barr, J.R. Detection of Botulinum Toxins A, B, E, and F in Foods by Endopep-MS. J. Agric. Food Chem. 2015, 63, 1133-1141. [CrossRef] [PubMed]
37. Kalb, S.R.; Baudys, J.; Wang, D.; Barr, J.R. Recommended mass spectrometry-based strategies to identify botulinum neurotoxin-containing samples. Toxins 2015, 7, 1765-1778. [CrossRef] [PubMed]
38. Kalb, S.R.; Moura, H.; Boyer, A.E.; McWilliams, L.G.; Pirkle, J.L.; Barr, J.R. The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples. Anal. Biochem. 2006, 351, 84-92. [CrossRef] [PubMed]
39. Kalb, S.R.; Garcia-Rodriguez, C.; Lou, J.; Baudys, J.; Smith, T.J.; Marks, J.D.; Smith, L.A.; Pirkle, J.L.; Barr, J.R. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One 2010, 5. [CrossRef] [PubMed]
40. Rosen, O.; Feldberg, L.; Gura, S.; Zichel, R. Improved detection of botulinum type E by rational design of a new peptide substrate for endopeptidase-mass spectrometry assay. Anal. Biochem. 2014, 456, 50-52. [CrossRef] [PubMed]
41. Wang, D.; Krilich, J.; Baudys, J.; Barr, J.R.; Kalb, S.R. Optimization of peptide substrates for botulinum neurotoxin E improves detection sensitivity in the Endopep-MS assay. Anal. Biochem. 2014, 468C, 15-21. [CrossRef] [PubMed]
42. Schantz, E.J.; Johnson, E.A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 1992, 56, 80-99. [PubMed]
43. Bryant, A.M.; Davis, J.; Cai, S.; Singh, B.R. Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum hall A strain. Protein J. 2013, 32, 106-117. [CrossRef] [PubMed]
44. Gornall, A.G.; Bardawill, C.J.; David, M.M. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. 1949, 177, 751-766. [PubMed]
45. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254. [CrossRef]
46. Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275. [PubMed]
47. McKenzie, H.A.; Wallace, H.S. The Kjeldahl determination of nitrogen: A critical study of digestion conditions. Aust. J. Chem. 1954, 7, 55-70. [CrossRef]
48. Bülbring, E. Observations on the isolated phrenic nerve diaphragm preparation of the rat. Br. J. Pharmacol. Chemother. 1946, 1, 38-61. [CrossRef] [PubMed]
49. Simpson, L.L.; Rapport, M.M. The binding of botulinum toxin to membrane lipids: Sphingolipids, steroids and fatty acids. J. Neurochem. 1971, 18, 1751-1759. [CrossRef] [PubMed]
50. Habermann, E.; Dreyer, F.; Bigalke, H. Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin. Naunyn. Schmiedebergs Arch. Pharmacol. 1980, 311, 33-40. [CrossRef] [PubMed]
51. Wohlfarth, K.; Goschel, H.; Frevert, J.; Dengler, R.; Bigalke, H. Botulinum A toxins: Units versus units. Naunyn. Schmiedebergs Arch. Pharmacol. 1997, 355, 335-340. [CrossRef] [PubMed]
52. EDQM. European Pharmacopoeia 5th ed., Council of Europe. 01/2005:2113. Botulinum Toxin Type A for Injection. Eur. Pharmacop. 2006, 1117-1119.
53. Sesardic, D.; Leung, T.; Gaines Das, R. Role for standards in assays of botulinum toxins: International collaborative study of three preparations of botulinum typeAtoxin. Biologicals 2003, 31, 265-276. [CrossRef] [PubMed]
54. Adler, S.; Bicker, G.; Bigalke, H.; Bishop, C.; Blumel, J.; Dressler, D.; Fitzgerald, J.; Gessler, F.; Heuschen, H.; Kegel, B.; et al. The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. Altern. Lab. Anim. 2010, 38, 315-330. [PubMed]
55. Sakaguchi, G. Clostridium botulinum toxins. Pharmacol. Ther. 1982, 19, 165-194. [CrossRef]
56. Rummel, A.; Eichner, T.; Weil, T.; Karnath, T.; Gutcaits, A.; Mahrhold, S.; Sandhoff, K.; Proia, R.L.; Acharya, K.R.; Bigalke, H.; et al. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl. Acad. Sci. USA 2007, 104, 359-364. [CrossRef] [PubMed]
57. Wang, J.; Meng, J.; Lawrence, G.W.; Zurawski, T.H.; Sasse, A.; Bodeker, M.O.; Gilmore, M.A.; Fernandez-Salas, E.; Francis, J.; Steward, L.E.; et al. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J. Biol. Chem. 2008, 283, 16993-17002. [CrossRef] [PubMed]
58. Wang, J.; Zurawski, T.H.; Meng, J.; Lawrence, G.W.; Aoki, K.R.; Wheeler, L.; Dolly, J.O. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. FASEB J. 2012, 26, 5035-5048. [CrossRef] [PubMed]
59. Wang, J.; Zurawski, T.H.; Bodeker, M.O.; Meng, J.; Boddul, S.; Aoki, K.R.; Dolly, J.O. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B. Biochem. J. 2012, 444, 59-67. [CrossRef] [PubMed]
60. Sikorra, S.; Henke, T.; Galli, T.; Binz, T. Substrate Recognition Mechanism of VAMP/Synaptobrevincleaving Clostridial Neurotoxins. J. Biol. Chem. 2008, 283, 21145-21152. [CrossRef] [PubMed]
61. Sugiyama, H. Clostridium botulinum neurotoxin. Microbiol. Rev. 1980, 44, 419-448. [PubMed]